Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia 4Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1Hodgkin Disease 1Congenital Abnormalities 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × Methylprednisolone Hemisuccinate × Clear all
NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡